Ana Aparicio, MD

Peer-Reviewed Articles

1. Venkatesh N, Tidwell RS, Yu Y, Aparicio A, Zurita AJ, Subudhi SK, Siddiqui BA, Mukhida SS, Gregg JR, Corn PG, Koutroumpakis E, McQuade JL, Frigo DE, Pilie PG, Huff C, Logothetis CJ, Hahn AW. Body composition in recurrent prostate cancer and the role of steroidogenic genotype. Endocr Relat Cancer 31(12):None, 2024. PMID: 39324992.
2. Guo S, Liu X, Cheng X, Jiang Y, Ji S, Liang Q, Koval A, Li Y, Owen LA, Kim IK, Aparicio A, Lee S, Sood AK, Kopetz S, Shen JP, Weinstein JN, DeAngelis MM, Chen R, Wang W. A deconvolution framework that uses single-cell sequencing plus a small benchmark dataset for accurate analysis of cell type ratios in complex tissue samples. Genome Res None(None):None, 2024. PMID: 39586714.
3. Schmidt MJ, Naghdloo A, Prabakar RK, Kamal M, Cadaneanu R, Garraway IP, Lewis M, Aparicio A, Zurita-Saavedra A, Corn P, Kuhn P, Pienta KJ, Amend SR, Hicks J. Polyploid cancer cells reveal signatures of chemotherapy resistance. Oncogene None(None):None, 2024. PMID: 39578659.
4. Serrano AG, Rocha P, Freitas Lima C, Stewart A, Zhang B, Diao L, Fujimoto J, Cardnell RJ, Lu W, Khan K, Sable B, Ellison AR, Wistuba II, Concannon KF, Halperin DM, Bogdan C, Sircar K, Zhang M, Cargill K, Wang Q, Aparicio A, Lazar A, Hernandez S, Estrella J, Ramalingam P, El-Naggar A, Kalhor N, Gay CM, Byers LA, Solis Soto LM. Delta-like ligand 3 (DLL3) landscape in pulmonary and extra-pulmonary neuroendocrine neoplasms. NPJ Precis Oncol 8(1):268, 2024. PMID: 39558076.
5. Koutroumpakis E, Venkatesh N, Aparicio A, Song J, Panaretakis T, Deswal A, Logothetis CJ, Frigo DE, Hahn AW. Leptin levels are associated with coronary artery calcification in patients with advanced prostate cancer. Oncologist None(None):None, 2024. PMID: 39557398.
6. Hicks J, Schmidt M, Nahgdloo A, Prabakar R, Kamal M, Cadaneanu R, Garraway I, Lewis M, Aparicio A, Zurita A, Corn P, Kuhn P, Pienta K, Amend S. Polyploid cancer cells reveal signatures of chemotherapy resistance. Res Sq None(None):None, 2024. PMID: 39483900.
7. Gillessen S, Turco F, Davis ID, Efstathiou JA, Fizazi K, James ND, Shore N, Small E, Smith M, Sweeney CJ, Tombal B, Zilli T, Agarwal N, Antonarakis ES, Aparicio A, Armstrong AJ, Bastos DA, Attard G, Axcrona K, Ayadi M, Beltran H, Bjartell A, Blanchard P, Bourlon MT, Briganti A, Bulbul M, Buttigliero C, Caffo O, Castellano D, Castro E, Cheng HH, Chi KN, Clarke CS, Clarke N, de Bono JS, De Santis M, Duran I, Efstathiou E, Ekeke ON, El Nahas TIH, Emmett L, Fanti S, Fatiregun OA, Feng FY, Fong PCC, Fonteyne V, Fossati N, George DJ, Gleave ME, Gravis G, Halabi S, Heinrich D, Herrmann K, Hofman MS, Hope TA, Horvath LG, Hussain MHA, Jereczek-Fossa BA, Jones RJ, Joshua AM, Kanesvaran R, Keizman D, Khauli RB, Kramer G, Loeb S, Mahal BA, Maluf FC, Mateo J, Matheson D, Matikainen MP, McDermott R, McKay RR, Mehra N, Merseburger AS, Morgans AK, Morris MJ, Mrabti H, Mukherji D, Murphy DG, Murthy V, Mutambirwa SBA, Nguyen PL, Oh WK, Ost P, O'Sullivan JM, Padhani AR, Parker C, Poon DMC, Pritchard CC, Rabah DM, Rathkopf D, Reiter RE, Renard-Penna R, Ryan CJ, Saad F, Sade JP, Sandhu S, Sartor OA, Schaeffer E, Scher HI, Sharifi N, Skoneczna IA, Soule HR, Spratt DE, Srinivas S, Sternberg CN, Suzuki H, Taplin ME, Thellenberg-Karlsson C, Tilki D, Turkeri LN, Uemura H, Urun Y, Vale CL, Vapiwala N, Walz J, Yamoah K, Ye D, Yu EY, Zapatero A, Omlin A. Management of Patients with Advanced Prostate Cancer. Report from the 2024 Advanced Prostate Cancer Consensus Conference (APCCC). Eur Urol None(None):None, 2024. PMID: 39394013.
8. Jung W, Abdelnour A, Kaplonek P, Herrero R, Shih-Lu Lee J, Barbati DR, Chicz TM, Levine KS, Fantin RC, Loria V, Porras C, Lauffenburger DA, Gail MH, Aparicio A, Hildesheim A, Alter G, McNamara RP. SARS-CoV-2 infection prior to vaccination amplifies Fc-mediated humoral profiles in an age-dependent manner. Cell Rep 43(9):114684, 2024. PMID: 39213155.
9. Rathkopf DE, Patel MR, Choudhury AD, Rasco D, Lakhani N, Hawley JE, Srinivas S, Aparicio A, Narayan V, Runcie KD, Emamekhoo H, Reichert ZR, Nguyen MH, Wells AL, Kandimalla R, Liu C, Suryawanshi S, Han J, Wu J, Arora VK, Pourdehnad M, Armstrong AJ. Safety and clinical activity of BMS-986365 (CC-94676), a dual androgen receptor ligand-directed degrader and antagonist, in heavily pretreated patients with metastatic castration-resistant prostate cancer. Ann Oncol None(None):None, 2024. PMID: 39293515.
10. Schmidt MJ, Naghdloo A, Prabakar RK, Kamal M, Cadaneanu R, Garraway IP, Lewis M, Aparicio A, Zurita-Saavedra A, Corn P, Kuhn P, Pienta KJ, Amend SR, Hicks J. Polyploid cancer cells reveal signatures of chemotherapy resistance. bioRxiv None(None):None, 2024. PMID: 39229204.
11. Hahn AW, Tidwell RS, Pilie PG, Yu Y, Liu J, Surasi DS, Titus M, Zhang J, Venkatesh N, Panaretakis T, Gregg JR, Zurita AJ, Siddiqui BA, Corn PG, Subudhi SK, Msaouel P, Koutroumpakis E, Huff CD, Aparicio A, McQuade JL, Frigo DE, Logothetis CJ. Body composition as a determinant of the therapeutic index with androgen signaling inhibition. Prostate Cancer Prostatic Dis None(None):None, 2024. PMID: 39019979.
12. Jiang Y, Montierth MD, Yu K, Ji S, Guo S, Tran Q, Liu X, Shin SJ, Cao S, Li R, Tang Y, Lesluyes T, Kopetz S, Ajani J, Msaouel P, Subudhi SK, Aparicio A, Sharma P, Shen JP, Sood AK, Tarabichi M, Wang JR, Kimmel M, Loo PV, Zhu H, Wang W. Pan-cancer subclonal mutation analysis of 7,827 tumors predicts clinical outcome. bioRxiv None(None):None, 2024. PMID: 39005348.
13. Aparicio AM, Tidwell RSS, Yadav SS, Chen JS, Zhang M, Liu J, Guo S, Pilie PG, Yu Y, Song X, Vundavilli H, Jindal S, Zhu K, Viscuse PV, Lebenthal JM, Hahn AW, Soundararajan R, Corn PG, Zurita-Saavedra A, Subudhi SK, Zhang J, Wang W, Huff C, Troncoso P, Allison JP, Sharma P, Logothetis CJ. A Modular Trial of Androgen Signaling Inhibitor Combinations Testing a Risk-Adapted Strategy in Patients with Metastatic Castration-Resistant Prostate Cancer. Clin Cancer Res 30(13):2751-2763, 2024. PMID: 38683200.
14. Hahn A, Tidwell R, Pilie P, Yu Y, Liu J, Surasi D, Titus M, Zhang J, Venkatesh N, Panaretakis T, Gregg J, Zurita A, Siddiqui B, Corn P, Subudhi S, Msaouel P, Koutroumpakis E, Huff C, Aparicio A, McQuade J, Frigo D, Logothetis C. Body composition as a determinant of the therapeutic index with androgen signaling inhibition. Prostate Cancer and Prostatic Diseases None(None):None. e-Pub 2024. PMID: None.
15. Anselmino N, Labanca E, Shepherd PDA, Dong J, Yang J, Song X, Nandakumar S, Kundra R, Lee C, Schultz N, Zhang J, Araujo JC, Aparicio AM, Subudhi SK, Corn PG, Pisters LL, Ward JF, Davis JW, Vazquez ES, Gueron G, Logothetis CJ, Futreal A, Troncoso P, Chen Y, Navone NM. Integrative Molecular Analyses of the MD Anderson Prostate Cancer Patient-derived Xenograft (MDA PCa PDX) Series. Clin Cancer Res 30(10):2272-2285, 2024. e-Pub 2024. PMID: 38488813.
16. Franceschini GM, Quaini O, Mizuno K, Orlando F, Ciani Y, Ku SY, Sigouros M, Rothmann E, Alonso A, Benelli M, Nardella C, Auh J, Freeman D, Hanratty B, Adil M, Elemento O, Tagawa ST, Feng FY, Caffo O, Buttigliero C, Basso U, Nelson PS, Corey E, Haffner MC, Attard G, Aparicio A, Demichelis F, Beltran H. Non-invasive detection of neuroendocrine prostate cancer through targeted cell-free DNA methylation. Cancer Discov 14(3):424-445, 2024. e-Pub 2024. PMID: 38197680.
17. Viscuse PV, Slack-Tidwell RS, Zhang M, Rohra P, Zhu K, San Lucas FA, Konnick E, Pilie PG, Siddiqui B, Logothetis CJ, Corn P, Subudhi SK, Pritchard CC, Soundararajan R, Aparicio A. Evaluation of the Aggressive-Variant Prostate Cancer Molecular Signature in Clinical Laboratory Improvement Amendments (CLIA) Environments. Cancers (Basel) 15(24), 2023. e-Pub 2023. PMID: 38136389.
18. Guo S, Liu X, Cheng X, Jiang Y, Ji S, Liang Q, Koval A, Li Y, Owen LA, Kim IK, Aparicio A, Shen JP, Kopetz S, Weinstein JN, DeAngelis MM, Chen R, Wang W. The DeMixSC deconvolution framework uses single-cell sequencing plus a small benchmark dataset for improved analysis of cell-type ratios in complex tissue samples. bioRxiv, 2023. e-Pub 2023. PMID: 37873318.
19. Aparicio A. Biochemical Recurrence in Prostate Cancer - Tilting the Scale. N Engl J Med 389(16):1522-1523, 2023. PMID: 37851879.
20. Andring LM, Abu-Gheida I, Bathala T, Yoder AK, Manzar GS, Maldonado JA, Frank SJ, Choi S, Nguyen QN, Hoffman K, McGuire SE, Mok H, Aparicio A, Chapin BF, Tang C. Definitive local therapy for T4 prostate cancer associated with improved local control and survival. BJU Int 132(3):307-313, 2023. e-Pub 2023. PMID: 37057728.
21. Hahn AW, Thoman W, Koutroumpakis E, Abdulla A, Subudhi SK, Aparicio A, Basen-Enngquist K, Logothetis CJ, Gilchrist SC. Cardiometabolic healthcare for men with prostate cancer: an MD Anderson Cancer Center experience. Cardiooncology 9(1):33, 2023. e-Pub 2023. PMID: 37705024.
22. Wang K, Kumar T, Wang J, Minussi DC, Sei E, Li J, Tran TM, Thennavan A, Hu M, Casasent AK, Xiao Z, Bai S, Yang L, King LM, Shah V, Kristel P, van der Borden CL, Marks JR, Zhao Y, Zurita AJ, Aparicio A, Chapin B, Ye J, Zhang J, Gibbons DL, PRECISION Consortium GC, Sawyer E, Thompson AM, Futreal A, Hwang ES, Wesseling J, Lips EH, Navin NE. Archival single-cell genomics reveals persistent subclones during DCIS progression. Cell 186(18):3968-3982.e15, 2023. e-Pub 2023. PMID: 37586362.
23. Tang C, Sherry AD, Haymaker C, Bathala T, Liu S, Fellman B, Cohen L, Aparicio A, Zurita AJ, Reuben A, Marmonti E, Chun SG, Reddy JP, Ghia A, McGuire S, Efstathiou E, Wang J, Wang J, Pilie P, Kovitz C, Du W, Simiele SJ, Kumar R, Borghero Y, Shi Z, Chapin B, Gomez D, Wistuba I, Corn PG. Addition of Metastasis-Directed Therapy to Intermittent Hormone Therapy for Oligometastatic Prostate Cancer: The EXTEND Phase 2 Randomized Clinical Trial. JAMA Oncol 9(6):825-834, 2023. e-Pub 2023. PMID: 37022702.
24. Moreno A, Solanki AA, Xu T, Lin R, Palta J, Daugherty E, Hong D, Hong J, Kamran SC, Katsoulakis E, Brock K, Feng M, Fuller C, Mayo C, Cancer Consortium BP. Identification of Key Elements in Prostate Cancer for Ontology Building via a Multidisciplinary Consensus Agreement. None, 2023. PMID: 37370731.
25. Gillessen S, Bossi A, Davis ID, de Bono J, Fizazi K, James ND, Mottet N, Shore N, Small E, Smith M, Sweeney CJ, Tombal B, Antonarakis ES, Aparicio AM, Armstrong AJ, Attard G, Beer TM, Beltran H, Bjartell A, Blanchard P, Briganti A, Bristow RG, Bulbul M, Caffo O, Castellano D, Castro E, Cheng HH, Chi KN, Chowdhury S, Clarke CS, Clarke N, Daugaard G, De Santis M, Duran I, Eeles R, Efstathiou E, Efstathiou J, Ekeke ON, Evans CP, Fanti S, Feng FY, Fonteyne V, Fossati N, Frydenberg M, George D, Gleave M, Gravis G, Halabi S, Heinrich D, Herrmann K, Higano C, Hofman MS, Horvath LG, Hussain M, Jereczek-Fossa BA, Jones R, Kanesvaran R, Kellokumpu-Lehtinen PL, Khauli RB, Klotz L, Kramer G, Leibowitz R, Logothetis C, Mahal B, Maluf F, Mateo J, Matheson D, Mehra N, Merseburger A, Morgans AK, Morris MJ, Mrabti H, Mukherji D, Murphy DG, Murthy V, Nguyen PL, Oh WK, Ost P, O'Sullivan JM, Padhani AR, Pezaro CJ, Poon DMC, Pritchard CC, Rabah DM, Rathkopf D, Reiter RE, Rubin MA, Ryan CJ, Saad F, Sade JP, Sartor O, Scher HI, Sharifi N, Skoneczna I, Soule H, Spratt DE, Srinivas S, Sternberg CN, Steuber T, Suzuki H, Sydes MR, Taplin ME, Tilki D, Türkeri L, Turco F, Uemura H, Uemura H, Ürün Y, Vale CL, van Oort I, Vapiwala N, Walz J, Yamoah K, Ye D, Yu EY, Zapatero A, Zilli T, Omlin A. Management of patients with advanced prostate cancer-metastatic and/or castration-resistant prostate cancer: Report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022. Eur J Cancer 185:178-215, 2023. e-Pub 2023. PMID: 37003085.
26. Shi W, Wang Y, Zhao Y, Kim JJ, Li H, Meng C, Chen F, Zhang J, Mak DH, Van V, Leo J, St Croix B, Aparicio A, Zhao D. Immune checkpoint B7-H3 is a therapeutic vulnerability in prostate cancer harboring PTEN and TP53 deficiencies. Sci Transl Med 15(695):eadf6724, 2023. e-Pub 2023. PMID: 37163614.
27. Gillessen S, Bossi A, Davis ID, de Bono J, Fizazi K, James ND, Mottet N, Shore N, Small E, Smith M, Sweeney C, Tombal B, Antonarakis ES, Aparicio AM, Armstrong AJ, Attard G, Beer TM, Beltran H, Bjartell A, Blanchard P, Briganti A, Bristow RG, Bulbul M, Caffo O, Castellano D, Castro E, Cheng HH, Chi KN, Chowdhury S, Clarke CS, Clarke N, Daugaard G, De Santis M, Duran I, Eeles R, Efstathiou E, Efstathiou J, Ngozi Ekeke O, Evans CP, Fanti S, Feng FY, Fonteyne V, Fossati N, Frydenberg M, George D, Gleave M, Gravis G, Halabi S, Heinrich D, Herrmann K, Higano C, Hofman MS, Horvath LG, Hussain M, Jereczek-Fossa BA, Jones R, Kanesvaran R, Kellokumpu-Lehtinen PL, Khauli RB, Klotz L, Kramer G, Leibowitz R, Logothetis CJ, Mahal BA, Maluf F, Mateo J, Matheson D, Mehra N, Merseburger A, Morgans AK, Morris MJ, Mrabti H, Mukherji D, Murphy DG, Murthy V, Nguyen PL, Oh WK, Ost P, O'Sullivan JM, Padhani AR, Pezaro C, Poon DMC, Pritchard CC, Rabah DM, Rathkopf D, Reiter RE, Rubin MA, Ryan CJ, Saad F, Pablo Sade J, Sartor OA, Scher HI, Sharifi N, Skoneczna I, Soule H, Spratt DE, Srinivas S, Sternberg CN, Steuber T, Suzuki H, Sydes MR, Taplin ME, Tilki D, Türkeri L, Turco F, Uemura H, Uemura H, Ürün Y, Vale CL, van Oort I, Vapiwala N, Walz J, Yamoah K, Ye D, Yu EY, Zapatero A, Zilli T, Omlin A. Management of Patients with Advanced Prostate Cancer. Part I: Intermediate-/High-risk and Locally Advanced Disease, Biochemical Relapse, and Side Effects of Hormonal Treatment: Report of the Advanced Prostate Cancer Consensus Conference 2022. Eur Urol 83(3):267-293, 2023. e-Pub 2022. PMID: 36494221.
28. Yao J, Bergsland E, Aggarwal R, Aparicio A, Beltran H, Crabtree JS, Hann CL, Ibrahim T, Byers LA, Sasano H, Umejiego J, Pavel M. DLL3 as an Emerging Target for the Treatment of Neuroendocrine Neoplasms. Oncologist 27(11):940-951, 2022. e-Pub 2022. PMID: 35983951.
29. Li H, Wang Y, Lin K, Venkadakrishnan VB, Bakht M, Shi W, Meng C, Zhang J, Tremble K, Liang X, Song JH, Feng X, Van V, Deng P, Burks JK, Aparicio A, Keyomarsi K, Chen J, Lu Y, Beltran H, Zhao D. CHD1 promotes sensitivity to Aurora kinase inhibitors by suppressing interaction of AURKA with its coactivator TPX2. Cancer Res 82(17):3088-3101, 2022. e-Pub 2022. PMID: 35771632.
30. Zhang B, Stewart CA, Wang Q, Cardnell RJ, Rocha P, Fujimoto J, Solis Soto LM, Wang R, Novegil V, Ansell P, He L, Fernandez L, Jendrisak A, Gilbertson C, Schonhoft JD, Byun J, Jones J, Anderson AKL, Aparicio A, Tran H, Negrao MV, Zhang J, Wang WL, Wistuba II, Wang J, Wenstrup R, Byers LA, Gay CM. Dynamic expression of Schlafen 11 (SLFN11) in circulating tumour cells as a liquid biomarker in small cell lung cancer. Br J Cancer 127(3):569-576, 2022. e-Pub 2022. PMID: 35440668.
31. Soundararajan R, Viscuse P, Pilie P, Liu J, Logotheti S, Laberiano Fernández C, Lorenzini D, Hoang A, Lu W, Soto LMS, Wistuba II, Xu M, Song X, Shepherd PDA, Navone NM, Tidwell RSS, Lozano G, Logothetis C, Zhang J, Long JP, Estecio MR, Tzelepi V, Aparicio AM. Genotype-to-Phenotype Associations in the Aggressive Variant Prostate Cancer Molecular Profile (AVPC-m) Components. Cancers (Basel) 14(13), 2022. e-Pub 2022. PMID: 35805010.
32. Chai S, Ruiz-Velasco C, Naghdloo A, Pore M, Singh M, Matsumoto N, Kolatkar A, Xu L, Shishido S, Aparicio A, Zurita AJ, Hicks J, Kuhn P. Identification of epithelial and mesenchymal circulating tumor cells in clonal lineage of an aggressive prostate cancer case. NPJ Precis Oncol 6(1):41, 2022. e-Pub 2022. PMID: 35729213.
33. Han, HH, Wang, Y, Curto, J, Gurrapu, S, Laudato, S, Rumandla, A, Chakraborty, G, Wang, X, Chen, H, Jiang, Y, Kumar, D, Caggiano, EG, Capogiri, M, Zhang, B, Ji, Y, Maity, S, Hu, M, Bai, S, Aparicio, A, Efstathiou, E, Logothetis, CJ, Navin, N, Navone, NM, Chen, Y, Giancotti, FG. Mesenchymal and stem-like prostate cancer linked to therapy-induced lineage plasticity and metastasis. Cell Reports 39(1), 2022. PMID: 35385726.
34. Ranasinghe WKB, Troncoso P, Surasi DS, Ibarra Rovira JJ, Bhosale P, Szklaruk J, Kokorovic A, Wang X, Elsheshtawi M, Zhang M, Aparicio A, Chapin BF, Bathala TK. Defining Diagnostic Criteria for Prostatic Ductal Adenocarcinoma at Multiparametric MRI. Radiology 303(1):204732, 2022. e-Pub 2022. PMID: 35076303.
35. Yadav D, Hwang H, Qiao W, Upadhyay R, Chapin BF, Tang C, Aparicio A, Lopez-Olivo MA, Kang SK, Macapinlac HA, Bathala TK, Surasi DS. 18F-fluciclovine versus PSMA PET Imaging in Primary Tumor Detection during Initial Staging of High-Risk Prostate Cancer: A Systematic Review and Meta-Analysis. Radiol Imaging Cancer 4(2):e210091, 2022. PMID: 35212559.
36. Chai S, Matsumoto N, Storgard R, Peng CC, Aparicio A, Ormseth B, Rappard K, Cunningham K, Kolatkar A, Nevarez R, Tu KH, Hsu CJ, Malihi P, Corn P, Zurita A, Hicks J, Kuhn P, Ruiz-Velasco C. Platelet-Coated Circulating Tumor Cells Are a Predictive Biomarker in Patients with Metastatic Castrate-Resistant Prostate Cancer. Mol Cancer Res 19(12):2036-2045, 2021. e-Pub 2021. PMID: 34462330.
37. Spetsieris N, Boukovala M, Alafis I, Davis J, Zurita A, Wang X, Tu SM, Chapin BF, Aparicio A, Corn P, Wang J, Subudhi SK, Araujo J, Papadopoulos J, Pruitt L, Weldon JA, Logothetis CJ, Efstathiou E. Abiraterone acetate plus prednisone in non-metastatic biochemically recurrent castration-naïve prostate cancer. Eur J Cancer 157:259-267, 2021. e-Pub 2021. PMID: 34536949.
38. Sarker D, Dawson NA, Aparicio AM, Dorff TB, Pantuck AJ, Vaishampayan UN, Henson L, Vasist L, Roy-Ghanta S, Gorczyca M, York W, Ganji G, Tolson J, de Bono JS. A Phase I, Open-Label, Dose-Finding Study of GSK2636771, a PI3Kβ Inhibitor, Administered with Enzalutamide in Patients with Metastatic Castration-Resistant Prostate Cancer. Clin Cancer Res 27(19):5248-5257, 2021. e-Pub 2021. PMID: 34281912.
39. Subudhi SK, Siddiqui BA, Aparicio AM, Yadav SS, Basu S, Chen H, Jindal S, Tidwell RSS, Varma A, Logothetis CJ, Allison JP, Corn PG, Sharma P. Combined CTLA-4 and PD-L1 blockade in patients with chemotherapy-naïve metastatic castration-resistant prostate cancer is associated with increased myeloid and neutrophil immune subsets in the bone microenvironment. J Immunother Cancer 9(10), 2021. PMID: 34663638.
40. Oke O, Ranasinghe W, Tang C, Shaaban S, Xiao L, Reichard CA, Anscher MS, Chapin BF, Aparicio A. Impact of Definitive Local Therapy in Men with Primary Small Cell Prostate Carcinoma. Eur Urol 80(3):389-390, 2021. e-Pub 2021. PMID: 33824032.
41. Msaouel P, Oromendia C, Siefker-Radtke AO, Tannir NM, Subudhi SK, Gao J, Wang Y, Siddiqui BA, Shah AY, Aparicio AM, Campbell MT, Zurita AJ, Shaw LK, Lopez LP, McCord H, Chakraborty SN, Perales J, Lu C, Van Alstine ML, Elashoff M, Logothetis C. Evaluation of Technology-Enabled Monitoring of Patient-Reported Outcomes to Detect and Treat Toxic Effects Linked to Immune Checkpoint Inhibitors. JAMA Netw Open 8(8):e2122998, 2021. e-Pub 2021. PMID: 34459906.
42. Siddiqui BA, Gheeya JS, Goswamy R, Bathala TK, Surasi DS, Gao J, Shah A, Campbell MT, Msaouel P, Goswami S, Wang J, Zurita AJ, Jonasch E, Corn PG, Aparicio AM, Siefker-Radtke AO, Sharma P, Subudhi SK, Tannir N. Durable Responses in Patients with Genitourinary Cancers Following Immune Checkpoint Therapy Rechallenge after Moderate to Severe Immune-Related Adverse Events. J Immunother Cancer 9(7), 2021. PMID: 34326169.
43. Quinn DI, Tsao-Wei DD, Twardowski P, Aparicio AM, Frankel P, Chatta G, Wright JJ, Groshen SG, Khoo S, Lenz HJ, Lara PN, Gandara DR, Newman E. Phase II study of the histone deacetylase inhibitor vorinostat (Suberoylanilide Hydroxamic Acid; SAHA) in recurrent or metastatic transitional cell carcinoma of the urothelium - an NCI-CTEP sponsored: California Cancer Consortium trial, NCI 6879. Invest New Drugs 39(3):812-820, 2021. e-Pub 2021. PMID: 33409898.
44. Gerdtsson AS, Setayesh SM, Malihi PD, Ruiz C, Carlsson A, Nevarez R, Matsumoto N, Gerdtsson E, Zurita A, Logothetis C, Corn PG, Aparicio AM, Hicks J, Kuhn P. Large Extracellular Vesicle Characterization and Association with Circulating Tumor Cells in Metastatic Castrate Resistant Prostate Cancer. Cancers (Basel) 13(5):1-15, 2021. e-Pub 2021. PMID: 33801459.
45. Spetsieris N, Boukovala M, Weldon JA, Tsikkinis A, Hoang A, Aparicio A, Tu SM, Araujo JC, Zurita AJ, Corn PG, Pagliaro L, Kim J, Wang J, Subudhi SK, Tannir NM, Logothetis CJ, Troncoso P, Wang X, Wen S, Efstathiou E. A Phase 2 Trial of Abiraterone Followed by Randomization to Addition of Dasatinib or Sunitinib in Men With Metastatic Castration-Resistant Prostate Cancer. Clin Genitourin Cancer 19(1):22-31.e5, 2021. e-Pub 2020. PMID: 32675015.
46. Ranasinghe, WK, Shapiro, DD, Hwang, H, Wang, X, Reichard, CA, Elsheshtawi, MA, Achim, M, Bathala, TK, Tang, C, Aparicio, A, Tu, S, Navone, NM, Thompson, T, Pisters, LL, Troncoso, P, Davis, JW, Chapin, BF. Ductal Prostate Cancers Demonstrate Poor Outcomes with Conventional Therapies. European urology 79(2):298-306, 2021. PMID: 33279304.
47. Palanisamy N, Yang J, Shepherd PDA, Li-Ning-Tapia EM, Labanca E, Manyam GC, Ravoori MK, Kundra V, Araujo JC, Efstathiou E, Pisters LL, Wan X, Wang X, Vazquez ES, Aparicio AM, Carskadon SL, Tomlins SA, Kunju LP, Chinnaiyan AM, Broom BM, Logothetis CJ, Troncoso P, Navone NM. The MD Anderson prostate cancer patient-derived xenograft series (MDA PCa PDX) captures the molecular landscape of prostate cancer and facilitates marker-driven therapy development. Clin Cancer Res 26(18):4933-4946, 2020. e-Pub 2020. PMID: 32576626.
48. Malihi PD, Graf RP, Rodriguez A, Ramesh N, Lee J, Sutton R, Jiles R, Ruiz Velasco C, Sei E, Kolatkar A, Logothetis C, Navin NE, Corn P, Aparicio AM, Dittamore R, Hicks J, Kuhn P, Zurita AJ. Single-cell circulating tumor cell analysis reveals genomic instability as a distinctive feature of aggressive prostate cancer. Clin Cancer Res 26(15):4143-4153, 2020. e-Pub 2020. PMID: 32341031.
49. Sang K, Murphy WA, Aparicio A, Subudhi SK. RS3PE Following Treatment With Combination of Hormonal Therapies Plus Ipilimumab in a Patient With Metastatic Prostate Cancer. Journal of Immunotherapy and Precision Oncology 3(3), 2020. e-Pub 2020. PMID: None.
50. Ranasinghe WKB, Brooks NA, Elsheshtawi MA, Davis JW, Bathala TK, Tang C, Troncoso P, Aparicio A, Tu SM, Pisters LL, Chapin BF. Patterns of metastases of prostatic ductal adenocarcinoma. Cancer. e-Pub 2020. PMID: 32453443.
51. Subudhi SK, Vence L, Zhao H, Blando J, Yadav SS, Xiong Q, Reuben A, Aparicio A, Corn PG, Chapin BF, Pisters LL, Troncoso P, Tidwell RS, Thall P, Wu CJ, Zhang J, Logothetis CL, Futreal A, Allison JP, Sharma P. Neoantigen responses, immune correlates, and favorable outcomes after ipilimumab treatment of patients with prostate cancer. Sci Transl Med 12(537), 2020. PMID: 32238575.
52. Abu-Gheida I, Bathala TK, Maldonado JA, Khan M, Anscher MS, Frank SJ, Choi S, Nguyen QN, Hoffman KE, McGuire SE, Kim M, Kuban DA, Aparicio A, Chapin BF, Tang C. Increased frequency of Mesorectal and Perirectal LN involvement in T4 Prostate Cancers. Int J Radiat Oncol Biol Phys. e-Pub 2020. PMID: 32353391.
53. Corn PG, Zhang M, Nogueras-Gonzalez GM, Xiao L, Zurita AJ, Subudhi SK, Tu SM, Aparicio AM, Coarfa C, Rajapakshe K, Huang S, Navone NM, Lin SH, Wang G, Ramachandran S, Titus MA, Panaretakis T, Gallick GE, Efstathiou E, Troncoso P, Logothetis C. A Phase II Study of Cabozantinib and Androgen Ablation in Patients with Hormone-Naïve Metastatic Prostate Cancer. Clin Cancer Res 26(5):990-999, 2020. e-Pub 2020. PMID: 31941830.
54. Bagley AF, Anscher MS, Choi S, Frank SJ, Hoffman KE, Kuban DA, McGuire SE, Nguyen QN, Chapin B, Aparicio A, Pezzi TA, Smith GL, Smith BD, Hess K, Tang C. Association of Sociodemographic and Health-Related Factors with Receipt of Nondefinitive Therapy Among Younger Men with High-Risk Prostate Cancer. JAMA Netw Open 3(3):e201255, 2020. e-Pub 2020. PMID: 32191331.
55. Boukovala M, Spetsieris N, Weldon JA, Tsikkinis A, Hoang A, Aparicio A, Tu SM, Araujo JC, Zurita AJ, Corn PG, Pagliaro L, Kim J, Wang J, Subudhi SK, Tannir NM, Logothetis CJ, Troncoso P, Wen S, Efstathiou E. A candidate androgen signaling signature predictive of response to abiraterone acetate in men with metastatic castration-resistant prostate cancer. Eur J Cancer 127:67-75. e-Pub 2020. PMID: 31986451.
56. Tzelepi V, Logotheti S, Efstathiou E, Troncoso P, Aparicio A, Sakellakis M, Hoang A, Perimenis P, Melachrinou M, Logothetis C, Zolota V. Epigenetics and prostate cancer: defining the timing of DNA methyltransferase deregulation during prostate cancer progression. Pathology. e-Pub 2019. PMID: 31864524.
57. Jiao S, Subudhi SK, Aparicio A, Ge Z, Guan B, Miura Y, Sharma P. Differences in Tumor Microenvironment Dictate T Helper Lineage Polarization and Response to Immune Checkpoint Therapy. Cell 179:1177-1190, 2019. PMID: None.
58. Corn PG, Heath EI, Zurita A, Ramesh N, Xiao L, Sei E, Li-Ning-Tapia E, Tu SM, Subudhi SK, Wang J, Wang X, Efstathiou E, Thompson TC, Troncoso P, Navin N, Logothetis CJ, Aparicio AM. Cabazitaxel plus carboplatin for the treatment of men with metastatic castration-resistant prostate cancers: a randomised, open-label, phase 1-2 trial. Lancet Oncol 20(10):1432-1443, 2019. e-Pub 2019. PMID: 31515154.
59. Goswami S, Apostolou I, Zhang J, Skepner J, Anandhan S, Zhang X, Xiong L, Trojer P, Aparicio A, Subudhi SK, Allison JP, Zhao H, Sharma P. Modulation of EZH2 expression in T cells improves efficacy of anti-CTLA-4 therapy. J Clin Invest 128(9):3813-3818, 2018. e-Pub 2018. PMID: 29905573.
60. Reichard CA, Gregg JR, Achim MF, Aparicio AM, Pettaway CA, Pisters LL, Ward JF, Davis JW, Chapin BF. Radical Prostatectomy in Metastatic Castration-resistant Prostate Cancer: Feasibility, Safety, and Quality of Life Outcomes. Eur Urol. e-Pub 2018. PMID: 29656854.
61. Zhang W, Liu B, Wu W, Li L, Broom BM, Basourakos SP, Korentzelos D, Luan Y, Wang J, Yang G, Park S, Azad AK, Cao X, Kim J, Corn PG, Logothetis CJ, Aparicio AM, Chinnaiyan AM, Navone N, Troncoso P, Thompson TC. Targeting the MYCN-PARP-DNA Damage Response Pathway inNeuroendocrine Prostate Cancer. Clin Cancer Res 24(3):696-707, 2018. e-Pub 2017. PMID: 29138344.
62. Bilen MA, Hess KR, Subudhi SK, Aparicio A, Kim J, Zurita-Saavedra AJ, Araujo JC, Corn PG, Stover J, Lin SH, Logothetis CJ, Tu SM. Clinical predictors of survival in patients with castration-resistant prostate cancer receiving sipuleucel-T cellular immunotherapy. Cancer Chemother Pharmacol 80(3):583-589, 2017. e-Pub 2017. PMID: 28730293.
63. Ganeshan D, Aparicio AM, Morani A, Kundra V. Pattern and Distribution of Distant Metastases in Anaplastic Prostate Carcinoma: A Single-Institute Experience With 101 Patients. AJR Am J Roentgenol 209(2):327-332, 2017. e-Pub 2017. PMID: 28590819.
64. Li L, Karanika S, Yang G, Wang J, Park S, Broom BM, Manyam GC, Wu W, Luo Y, Basourakos S, Song JH, Gallick GE, Karantanos T, Korentzelos D, Azad AK, Kim J, Corn PG, Aparicio AM, Logothetis CJ, Troncoso P, Heffernan T, Toniatti C, Lee HS, Lee JS, Zuo X, Chang W, Yin J, Thompson TC. Androgen receptor inhibitor-induced "BRCAness" and PARP inhibition are synthetically lethal for castration-resistant prostate cancer. Sci Signal 10(480), 2017. e-Pub 2017. PMID: 28536297.
65. Karanika S, Karantanos T, Li L, Wang J, Park S, Yang G, Zuo X, Song JH, Maity SN, Manyam GC, Broom B, Aparicio AM, Gallick GE, Troncoso P, Corn PG, Navone N, Zhang W, Li S, Thompson TC. Targeting DNA Damage Response in Prostate Cancer by Inhibiting Androgen Receptor-CDC6-ATR-Chk1 Signaling. Cell Rep 18(8):1970-1981, 2017. PMID: 28228262.
66. Ferrara F, Staquicini DI, Driessen WHP, D'Angelo S, Dobroff AS, Barry M, Lomo LC, Staquicini FI, Cardó-Vila M, Soghomonyan S, Alauddin MM, Flores LG, Arap MA, Lauer RC, Mathew P, Efstathiou E, Aparicio AM, Troncoso P, Navone NM, Logothetis CJ, Marchiò S, Gelovani JG, Sidman RL, Pasqualini R, Arap W. Targeted molecular-genetic imaging and ligand-directed therapy in aggressive variant prostate cancer. Proc Natl Acad Sci U S A 113(45):12786-12791, 2016. e-Pub 2016. PMID: 27791181.
67. Subudhi SK, Aparicio A, Gao J, Zurita AJ, Araujo JC, Logothetis CJ, Tahir SA, Korivi BR, Slack RS, Vence L, Emerson RO, Yusko E, Vignali M, Robins HS, Sun J, Allison JP, Sharma P. Clonal expansion of CD8 T cells in the systemic circulation precedes development of ipilimumab-induced toxicities. Proc Natl Acad Sci U S A 113(42):11919-11924, 2016. e-Pub 2016. PMID: 27698113.
68. Kleb B, Estécio MR, Zhang J, Tzelepi V, Chung W, Jelinek J, Navone NM, Tahir S, Marquez VE, Issa JP, Maity S, Aparicio A. Differentially methylated genes and androgen receptor re-expression in small cell prostate carcinomas. Epigenetics 11(3):0, 2016. e-Pub 2016. PMID: 26890396.
69. Aparicio AM, Shen L, Tapia EL, Lu JF, Chen HC, Zhang J, Wu G, Wang X, Troncoso P, Corn P, Thompson TC, Broom B, Baggerly K, Maity SN, Logothetis CJ. Combined Tumor Suppressor Defects Characterize Clinically Defined Aggressive Variant Prostate Cancers. Clin Cancer Res 22(6):1520-30, 2016. e-Pub 2015. PMID: 26546618.
70. Varkaris A, Corn PG, Parikh NU, Efstathiou E, Song JH, Lee YC, Aparicio A, Hoang AG, Gaur S, Thorpe L, Maity SN, Bar Eli M, Czerniak BA, Shao Y, Alauddin M, Lin SH, Logothetis CJ, Gallick GE. Integrating murine and clinical trials with cabozantinib to understand roles of MET and VEGFR-2 as targets for growth inhibition of prostate cancer. Clin Cancer Res 22(1):107-21, 2016. e-Pub 2015. PMID: 26272062.
71. Campbell MT, Millikan RE, Altinmakas E, Xiao L, Wen SJ, Siefker-Radtke AO, Aparicio A, Corn PG, Tannir NM. Phase I trial of sunitinib and temsirolimus in metastatic renal cell carcinoma. Clin Genitourin Cancer 13(3):218-24, 2015. e-Pub 2014. PMID: 25465491.
72. Bilen MA, Johnson MM, Mathew P, Pagliaro LC, Araujo JC, Aparicio A, Corn PG, Tannir NM, Wong FC, Fisch MJ, Logothetis CJ, Tu SM. Randomized phase 2 study of bone-targeted therapy containing strontium-89 in advanced castrate-sensitive prostate cancer. Cancer 1(121(1)):69-76, 2015. e-Pub 2014. PMID: 25155428.
73. Efstathiou E, Titus M, Wen S, Hoang A, Karlou M, Ashe R, Tu SM, Aparicio A, Troncoso P, Mohler J, Logothetis CJ. Molecular characterization of enzalutamide-treated bone metastatic castration-resistant prostate cancer. Eur Urol 67(1):53-60, 2015. e-Pub 2014. PMID: 24882673.
74. Wan X, Corn PG, Yang J, Palanisamy N, Starbuck MW, Efstathiou E, Li Ning Tapia EM, Tapia EM, Zurita AJ, Aparicio A, Ravoori MK, Vazquez ES, Robinson DR, Wu YM, Cao X, Iyer MK, McKeehan W, Kundra V, Wang F, Troncoso P, Chinnaiyan AM, Logothetis CJ, Navone NM. Prostate cancer cell-stromal cell crosstalk via FGFR1 mediates antitumor activity of dovitinib in bone metastases. (Research highlights on this article published in Nature Reviews Urology on September 23, 2014 and Cancer Discovery on September 25, 2014). Sci Transl Med 6(252):252ra122, 2014. PMID: 25186177.
75. Li L, Chang W, Yang G, Ren C, Park S, Karantanos T, Karhiou E, Maity SN, Aparicio AM, Li Ning Tapia EManika S, Wang J, Yin J, Shah PK, Takahiro H, Dobashi M, Zhang W, Efstat, Troncoso P, Broom B, Xiao L, Lee HS, Lee JS, Corn PG, Navone N, Thompson TC. Targeting poly(ADP-Ribose) polymerase and the c-Myb-regulated DNA damage response pathway in castration-resistant prostate cancer. Sci Signal 7(326):ra47, 2014. e-Pub 2014. PMID: 24847116.
76. Aparicio AM, Harzstark AL, Corn PG, Wen S, Araujo JC, Tu SM, Pagliaro LC, Kim J, Millikan RE, Ryan C, Tannir NM, Zurita AJ, Mathew P, Arap W, Troncoso P, Thall PF, Logothetis CJ. Platinum-based chemotherapy for variant castrate-resistant prostate cancer. Clin Cancer Res 19(13):3621-30, 2013. e-Pub 2013. PMID: 23649003.
77. Tannir NM, Plimack E, Ng C, Tamboli P, Bekele NB, Xiao L, Smith L, Lim Z, Pagliaro L, Araujo J, Aparicio A, Matin S, Wood CG, Jonasch E. A phase 2 trial of sunitinib in patients with advanced non-clear cell renal cell carcinoma. Eur Urol 62(6):1013-9, 2012. e-Pub 2012. PMID: 22771265.
78. Sircar K, Huang H, Hu L, Cogdell D, Dhillon J, Tzelepi V, Efstathiou E, Koumakpayi IH, Saad F, Luo D, Bismar TA, Aparicio A, Troncoso P, Navone N, Zhang W. Integrative molecular profiling reveals asparagine synthetase is a target in castration-resistant prostate cancer. Am J Pathol 180(3):895-903, 2012. e-Pub 2012. PMID: 22245216.
79. Tzelepi V, Zhang J, Lu JF, Kleb B, Wu G, Wan X, Hoang A, Efstathiou E, Sircar K, Navone NM, Troncoso P, Liang S, Logothetis CJ, Maity SN, Aparicio AM. Modeling lethal prostate cancer variant with small cell carcinoma features. Clin Cancer Res 18(3):666-77, 2012. e-Pub 2011. PMID: 22156612.
80. Bhatia S, Moon J, Margolin KA, Weber JS, Lao CD, Othus M, Aparicio AM, Ribas A, Sondak VK. Phase II trial of sorafenib in combination with carboplatin and paclitaxel in patients with metastatic uveal melanoma: SWOG S0512. PLoS One 7(11):e48787, 2012. e-Pub 2012. PMID: 23226204.
81. Sonpavde G, Aparicio AM, Zhan F, North B, Delaune R, Garbo LE, Rousey SR, Weinstein RE, Xiao L, Boehm KA, Asmar L, Fleming MT, Galsky MD, Berry WR, Von Hoff DD. Azacitidine favorably modulates PSA kinetics correlating with plasma DNA LINE-1 hypomethylation in men with chemonaive castration-resistant prostate cancer. Urol Oncol 29(6):682-9, 2011. e-Pub 2009. PMID: 19959380.
82. Iqbal S, Tsao-Wei DD, Quinn DI, Gitlitz BJ, Groshen S, Aparicio A, Lenz HJ, El-Khoueiry A, Pinski J, Garcia AA. Phase I clinical trial of pegylated liposomal doxorubicin and docetaxel in patients with advanced solid tumors. Am J Clin Oncol 34(1):27-31, 2011. e-Pub 2010. PMID: 20142723.
83. Guo CC, Dancer JY, Wang Y, Aparicio A, Navone NM, Troncoso P, Czerniak BA. TMPRSS2-ERG gene fusion in small cell carcinoma of the prostate. Hum Pathol 42(1):11-7, 2011. e-Pub 2010. PMID: 21040948.
84. Jonasch E, Corn P, Pagliaro LC, Warneke CL, Johnson MM, Tamboli P, Ng C, Aparicio A, Ashe RG, Wright JJ, Tannir NM. Upfront randomized phase II trial of sorafenib versus sorafenib and low-dose interferon alpha in patients with advanced renal cell carcinoma: clinical and biomarker analysis. Cancer 116(1):57-65, 2010. PMID: 19862815.
85. Jonasch E, Wood CG, Matin SF, Tu SM, Pagliaro LC, Corn PG, Aparicio A, Tamboli P, Millikan RE, Wang X, Araujo JC, Arap W, Tannir N. Phase II presurgical feasibility study of bevacizumab in untreated patients with metastatic renal cell carcinoma. J Clin Oncol 27(25):4076-81, 2009. e-Pub 2009. PMID: 19636008.
86. Gorlov IP, Byun J, Gorlova OY, Aparicio AM, Efstathiou E, Logothetis CJ. Candidate pathways and genes for prostate cancer: a meta-analysis of gene expression data. BMC Med Genomics 4(2):48, 2009. e-Pub 2009. PMID: 19653896.
87. Tu SM, Lopez A, Leibovici D, Bilen MA, Evliyaoglu F, Aparicio A, Guo CC, Kuban DA, Johnson MM, Pisters LL. Ductal adenocarcinoma of the prostate:clinical features and implications after local therapy. Cancer 115(13):2872-80, 2009. PMID: 19402048.
88. Aparicio A, North B, Barske L, Wang X, Bollati V, Weisenberger D, Yoo C, Tannir N, Horne E, Groshen S, Jones P, Yang A, Issa JP. LINE-1 methylation in plasma DNA as a biomarker of activity of DNA methylation inhibitors in patients with solid tumors. Epigenetics 4(3):176-84, 2009. e-Pub 2009. PMID: 19421002.
89. Luu TH, Morgan RJ, Leong L, Lim D, McNamara M, Portnow J, Frankel P, Smith DD, Doroshow JH, Wong C, Aparicio AM, Gandara DR, Somlo G. A phase II trial of vorinostat (suberoylanilide hydroxamic acid) in metastatic breast cancer: a California Cancer Consortium study. Clin Cancer Res 14(21):7138-42, 2008. PMID: 18981013.
90. Egger G, AM A, Escobar SG, Jones PA. Inhibition of histone deacetylation does not block resilencing of p16 after 5-aza-2'-deoxycytidine treatment. Cancer Res 67(1):346-53, 2007. PMID: 17210717.
91. Aparicio A, Eads C, Leong L, Laird PW, Newman N, Weber JS. Phase I trial of continuous infusion 5-Aza-2'-deoxyctidine (DAC). Cancer Chemother Pharmacol 51(3):231-39, 2003. PMID: 12655442.
92. Aparicio A, Gardner A, Tu Y, Savage A, Berenson J, Lichtenstein A. In vitro cytoreductive effects on multiple myeloma cells induced by bisphosphonates. Leukemia 12(2):220-29, 1998. PMID: 9519785.
93. Aparicio A. CHD1 Loss Hijacks SREBP2-mediated Cholesterol Biosynthesis to Fuel SPOP-deficient Prostate Cancer and Confers Resistance to Castration. None None(None):None. PMID: None.

Invited Articles

1. Berchuck JE, Viscuse PV, Beltran H, Aparicio A. Clinical considerations for the management of androgen indifferent prostate cancer. Prostate Cancer Prostatic Dis 24(3):623-637, 2021. e-Pub 2021. PMID: 33568748.
2. Laudato S, Aparicio A, Giancotti FG. Clonal Evolution and Epithelial Plasticity in the Emergence of AR-Independent Prostate Carcinoma. Trends Cancer 5(7):440-455, 2019. e-Pub 2019. PMID: 31311658.
3. Logothetis CJ, Aparicio A, Koinis F, Corn PG, Efstathiou E. Prostate Cancer: Quo Vadis?. Eur Urol. e-Pub 2019. PMID: 31300238.
4. Meeks JJ, Goldkorn A, Aparicio AM, McConkey DJ. Development of a translational medicine protocol for an NCTN genitourinary clinical trial: Critical steps, common pitfalls and a basic guide to translational clinical research. Urol Oncol 37(5):313-317, 2019. e-Pub 2018. PMID: 30115512.
5. Soundararajan R, Paranjape AN, Maity S, Aparicio A, Mani SA. EMT, stemness and tumor plasticity in aggressive variant neuroendocrine prostate cancers. Biochim Biophys Acta Rev Cancer 1870(2):229-238, 2018. e-Pub 2018. PMID: 29981816.
6. Metcalfe MJ, Smaldone MC, Lin DW, Aparicio AM, Chapin BF. Role of radical prostatectomy in metastatic prostate cancer: A review. Urol Oncol 35(4):125-134, 2017. e-Pub 2017. PMID: 28190749.
7. Basourakos SP, Li L, Aparicio AM, Corn PG, Kim J, Thompson TC. Combination Platinum-based and DNA Damage Response-targeting Cancer Therapy: Evolution and Future Directions. Curr Med Chem 24(15):1586-1606, 2017. e-Pub 2016. PMID: 27978798.
8. Goswami S, Aparicio A, Subudhi SK. Immune Checkpoint Therapies in Prostate Cancer. Cancer J 22(2):117-20, 2016. PMID: 27111907.
9. Aparicio A, Tzelepi V. Neuroendocrine (small-cell) carcinomas: why they teach us essential lessons about prostate cancer. Oncology (Williston Park) 28(10):831-8, 2014. e-Pub 2014. PMID: 25323607.
10. Beltran H, Tomlins S, Aparicio A, Arora V, Rickman D, Ayala G, Huang J, True L, Gleave ME, Soule H, Logothetis C, Rubin MA. Aggressive variants of castration-resistant prostate cancer. Clin Cancer Res 20(11):2846-50, 2014. e-Pub 2014. PMID: 24727321.
11. Logothetis CJ, Gallick GE, Maity SN, Kim J, Aparicio A, Efstathiou E, Lin SH. Molecular classification of prostate cancer progression: foundation for marker-driven treatment of prostate cancer. Cancer Discov 3(8):849-61, 2013. e-Pub 2013. PMID: 23811619.
12. Aparicio A, Den RB, Knudsen KE. Time to stratify? The retinoblastoma protein in castrate-resistant prostate cancer. Nat Rev Urol 8(10):562-8, 2011. e-Pub 2011. PMID: 21811228.
13. Alva AS, Hahn NM, Aparicio AM, Singal R, Yellapragada S, Sonpavde G. Hypomethylating agents for urologic cancers. Future Oncol 7(3)(3):447-63, 2011. PMID: 21417907.
14. Albany C, Alva AS, Aparicio AM, Singal R, Yellapragada S, Sonpavde G, Hahn NM. Epigenetics in prostate cancer. Prostate Cancer 2011:580318, 2011. e-Pub 2011. PMID: 22191037.
15. Aparicio A. The potential of histone deacetylase inhibitors in lung cancer. Clin Lung Cancer 7(5)(5):309-12, 2006. PMID: 16640801.
16. Aparicio AM, Elkhouiery AB, Quinn DI. The current and future application of adjuvant systemic chemotherapy in patients with bladder cancer following cystectomy. Urol Clin North Am 32(2):217-30, 2005. PMID: 15862619.
17. Egger G, Liang G, Aparicio A, Jones PA. Epigenetics in human disease and prospects for epigenetic therapy. Nature 429(6990):457-63, 2004. PMID: 15164071.
18. Aparicio A, Chamberlain MC. Neoplastic meningitis. Curr Neurol Neurosci Rep 2(3):225-35, 2002. PMID: 11937001.
19. Aparicio A, Weber JS. Review of the clinical experience with 5-Azacytidine and 5-Aza-2'-deoxycytidine in solid tumors. Curr Opin Investig Drugs 3(4):627-33, 2002. PMID: 12090735.
20. Weber JS, Aparicio A. Novel immunologic approaches to the management of malignant melanoma. Curr Opin Oncol 13(2):124-28, 2001. PMID: 11224710.

Other Articles

1. Hahn AW, Aparicio A, Jadvar H, Poon DMC MDT perspective: innovative applications of stereotactic body radiation therapy in metastatic castration-resistant prostate cancer. Prostate Cancer Prostatic Dis None(None):None, 2024. PMID: 39558122.
2. Crawford, Bryce, Hussain, Agarwal, Beltran, Cooperberg, Petrylak, Shore, Spratt, Tagawa, Antonarakis, Aparicio, Armstrong, Boike, Calais, Carducci, Chapin, Cookson, Davis, Dorff, Eggener, Feng, Gleave, Higano, Iagaru, Morgans, Morris, Murray, Poage, Rettig, Sartor, Scher, Sieber, Small, Srinivas, Yu, Zhang, Koo Expert Perspectives on Controversies in Castration-Sensitive Prostate Cancer Management: Narrative Review and Report of the First US Prostate Cancer Conference Part 1. JU Open Plus 2(4):29, 2024. PMID: 38774466.
3. Bryce, Crawford, Agarwal, Hussain, Beltran, Cooperberg, Petrylak, Shore, Spratt, Tagawa, Antonarakis, Aparicio, Armstrong, Boike, Calais, Carducci, Chapin, Cookson, Davis, Dorff, Eggener, Feng, Gleave, Higano, Iagaru, Morgans, Morris, Murray, Poage, Rettig, Sartor, Scher, Sieber, Small, Srinivas, Yu, Zhang, Koo Expert Perspectives on Controversies in Castration-Sensitive Prostate Cancer Management: Narrative Review and Report of the First US Prostate Cancer Conference Part 2. JU Open Plus 2(4):32, 2024. PMID: 38774467.
4. Ranasinghe W, Shapiro DD, Zhang M, Bathala T, Navone N, Thompson TC, Broom B, Aparicio A, Tu SM, Tang C, Davis JW, Pisters L, Chapin BF Optimizing the diagnosis and management of ductal prostate cancer. Nat Rev Urol 18(6):337-358, 2021. PMID: 33824525.
5. Soundararajan R, Aparicio AM, Logothetis CJ, Mani SA, Maity SN Function of Tumor Suppressors in Resistance to Antiandrogen Therapy and Luminal Epithelial Plasticity of Aggressive Variant Neuroendocrine Prostate Cancers. Front Oncol 8:69, 2018. PMID: 29600194.
6. Gao J, He Q, Subudhi S, Aparicio A, Zurita-Saavedra A, Lee DH, Jimenez C, Suarez-Almazor M, Sharma P Review of immune-related adverse events in prostate cancer patients treated with ipilimumab: MD Anderson experience. Oncogene 34(43):5411-7, 2015. PMID: 25659583.
7. Chapin BF, McGuire SE, Aparicio AM Local Therapy in Metastic Prostate Cancer: Does an Integrated Approach Improve Clinical Outcomes?. 2015 Genitourinary Cancers Symposium Daily News(2), 2015. PMID: None.
8. Aparicio AM Prostate Cancer: Clinical practitioner perspective. Endocrine News, 2011. PMID: None.
9. Aparicio A, Tzelepi V, Araujo JC, Guo CC, Liang S, Troncoso P, Logothetis CJ, Navone NM, Maity SN Neuroendocrine prostate cancer xenografts with large-cell and small-cell features derived from a single patient's tumor: Morphological, immunohistochemical and gene expression profiles. Prostate 71(8):846-56, 2011. PMID: 21456067.
10. Sonpavde G, Aparicio A, Guttierez I, Boehm KA, Hutson TE, Berry WR, Asmar L, von Hoff DD Phase II study of azacitidine to restore responsiveness of prostate cancer to hormonal therapy. Clin Genitourin Cancer 5(7):457-9, 2007. PMID: 18272030.

Editorials

1. Hahn AW, Koutroumpakis E, Narayan V, Aparicio A. The need for precision medicine in managing cardiovascular risk for men receiving ADT. Prostate Cancer Prostatic Dis None(None):None, 2024. PMID: 38796515.
2. Aparicio A. Biochemical Recurrence in Prostate Cancer - Tilting the Scale. New England Journal of Medicine 389(16):1522-1523, 2023. PMID: 37851879.
3. Logothetis C, Aparicio A, Thompson TC. ER stress in prostate cancer: A therapeutically exploitable vulnerability?. Sci Transl Med 10(439), 2018. PMID: 29720450.
4. Logothetis CJ, Aparicio AM. Is It Time to Re-Examine Prostate Cancer Treatment Paradigm by Targeting the Interaction Between the Prostate and Metastases?. J Clin Oncol 34(24):2810-1, 2016. PMID: 27432923.
5. Chapin BF, McGuire SE, Aparicio A. Is treatment of the primary tumor in metastatic prostate cancer justified?. Eur Urol 65(6):1067-8, 2014. PMID: 24411278.
6. Goldkorn A, Aparicio AM, Quinn DI. Therapeutic windows and opportunity cost cast upon prostate cancer's fatal shore. Ann Oncol 24(7):1717-20, 2013. PMID: 23798673.
7. Aparicio A, Logothetis CJ, Maity SN. Understanding the lethal variant of prostate cancer: Power of examining extremes. Cancer Discov 1(6):466-8, 2011. PMID: 22586648.

Abstracts

1. Viscuse P, Zhang M, Rohra P, Tidwell R, Pritchard C, Subudhi S, Pilie P, Logothetis C, Corn P, Aparicio A. Evaluation of the aggressive variant prostate cancer molecular profile (AVPCm) in CLIA environments. 2023 GU ASCO, 2023. PMID: None.
2. Pilie P, Tidwell R, Viscuse P, Subudhi S, Corn P, Tu S, Araujo J, Zurits A, Wang J, Efstathiou E, Deinert J, Logothetis C, Thompson T, Aparicio A. Randomized phase II study of olaparib (Ola) maintenance following cabazitaxel-carboplatin induction chemotherapy (CabCarb) in men with aggressive variant prostate cancer (AVPC). 2023 GU ASCO, 2023. PMID: None.
3. Hahn AW, Tidwell R, Thoman W, Abdulla A, Koutroumpakis E, Aparicio A, Subudhi S, Siddiqui B, Pilie P, Zurita A, Corn P, Laccetti A, Jana B, Basen-Engquist K, Logothetis C. A phase II trial modifying metabolic syndrome and cardiovascular risk for patients with prostate cancer on ADT using a risk factor modification program and continuous Fitbit monitoring (ProTrio). None, 2023. PMID: None.
4. Viscuse P, Tidwell R, Liu J, Guo S, Vundavilli H, Zhang M, Subudhi S, Zurita A, Corn P, Tu S, Araujo J, Wang J, Efstathiou E, Wang J, Pilié P, Troncoso P, Zhang J, Wang W, Logothetis C, Aparicio A. DynAMo: A dynamic allocation modular sequential trial of approved and promising therapies in men with metastatic CRPC. 2022 ASCO, 2022. PMID: None.
5. Efstathiou E, Boukovala M, Spetsieris N, Wen S, Hoang A, Weldon JA, Tidwell R, Davis JW, Chapin BF, Corn PG, Subudhi SK, Aparicio A, Pettaway CA, Pister LL, Papadopoulos JN, Adibi M, Wang J, Zurita AJ, Logothetis C, Troncoso P. Neoadjuvant Apalutamide (APA) plus Leuprolide (LHRHa) With or Without Abiraterone (AA) in Localized High-risk Prostate Cancer (LHRPC). 2020 ASCO Virtual Scientific Program, 2020. PMID: None.
6. Zhang M, A A, Wang X, Chapin B, Troncoso P. Aggressive Variant Prostate Cancer in Men with Hormone Naïve, de novo Metastatic Prostate Cancer (M1PC). United States & Canadian Academy of Pathology's 109th Annual Meeting, 2019. e-Pub 2019. PMID: None.
7. Aparicio A, Zhang M, Ramesh N, Xuemei W, Corn P, Zurita A, Davis J, Pettaway C, Adibi M, Mcguire S, Tu SM, Wang J, Subudhi S, Elesheshtai M, Efstathiou E, Logothetis C, Navin N, Troncoso P, Chapin BF. Aggressive variant prostate cancer (AVPC) molecular signature in castration-sensitive, de novo metastatic prostate cancer (M1PCa). 2019 ASCO, 2019. PMID: None.
8. Zurita A, Tidwell RS, Troncoso P, Chapin BF, Harris D, Pisters LL, Araujo JC, Pettaway CA, Aparicio A, Tu SM, Papadopoulos JN, Wang J, Logothetis C, Pagliaro LC, Davis JW. Randomized phase II trial of presurgical androgen deprivation therapy (ADT) with or without axitinib in prostate cancer (PCa) presenting with lymph node (LN) metastasis. 2019 ASCO, 2019. PMID: None.
9. Subudhi S, Aparicio A, Zurita A, Doger B, Kelly WK, Peer A, Rathkopf D, Karsh L, Tryon JJ, Kothrari N, Zhao X, Zhu E, Ricce D, Tran N, DeBono J. A phase Ib/II study of niraparib combination therapies for the treatment of metastatic castration-resistant prostate cancer (NCT03431350). 2019 ASCO, 2019. PMID: None.
10. Siddiqui B, Durand J, Gao J, Wang J, Aparicio A, Campbell MT, Siefker-Radtke AO, Tannir NM, Corn PG, Msaouel P, Shah AY, Zurita AJ, Tu SM, Suarez-Almazor ME, Sudhakar T, Logothetis C, Sharma P, Subudhi SK. Clinical and immunological analyses of immune checkpoint inhibitor-associated neuromuscular (NM) toxicities. 2019 ASCO, 2019. PMID: None.
11. Chapin BF, Wang X, Zhang M, Corn P, Zurita AJ, Elsheshtawi MA, Davis JW, Pettaway CA, Adibi M, Gleave M, Cooperberg MR, Smaldone MC, Mcguire SE, Tu SM, Wang J, Subudhi SK, Efstathiou E, Logothetis C, Troncoso P, Aparicio A. Complex biologic heterogeneity of de novo hormone naive metastatic prostate cancer (HNPCa): Comparison of early progressors and prolonged responders to initial systemic treatment. 2019 ASCO, 2019. PMID: None.
12. Oke O, Tang C, Shaaban S, Xiao L, Reichard CA, Chapin BF, Anscher MS, Aparicio A. Impact of definitive local therapy (LT) in men with primary small cell (or poorly differentiated neuroendocrine) prostate carcinomas (pSCPC). 2018 ASCO, 2018. PMID: None.
13. Efstathiou E, Wang X, Zurita A, Tu SM, Aparicio A, Wang J, Corn PG, Subudhi SK, Araujo JC, Reece LK, Pruitt L, Vanalstine ML, Logothetis C. A randomized study of finite abiraterone acetate (AA) plus leuprolide (LHRHa) versus LHRHa in biochemically recurrent non metastatic hormone naive prostate cancer (M0HNPC). 2018 ASCO, 2018. PMID: None.
14. Reichard CA, Gregg J, Achim MF, Aparicio A, Pisters LL, Ward JF, Davis JW, Chapin BF. Radical prostatectomy in metastatic castration-resistant prostate cancer: Feasibility, safety, and quality of life outcomes. Genitourinary Cancers Symposium, 2018. PMID: None.
15. Corn PG, Subudhi SK, Araujo JC, Vardake I, Aparicio A, Tu SM, Pagliaro LC, Zurita AJ, Logothetis C, Panaretakis T. Molecular profiling of liquid biopsies from patients (pts) with bone metastatic castration-resistant prostate cancer (BM-CRPC) treated with radium-223 (RA-223) to reveal differential enrichment for markers that correlate with overall survival (OS). Genitourinary Cancers Symposium, 2018. PMID: None.
16. Aparicio A, Gallichotte E, Cheng H, Yoo SY, Maity S, Logothetis CJ, Tewari M. Circulating micro-RNAs can detect adaptive response to therapy and aggressive subset of prostate cancer. 2013 AACR Annual Conference, 2013. PMID: None.
17. Aparicio A, Maity S, Wang X, Hoang AG, Efstathiou E, Troncoso P, Logothetis CJ. A molecular characterization of the anaplastic prostate carcinomas. 2013 AACR Annual Conference, 2013. PMID: None.
18. Corn PG, Varkaris A, Li Ning Tapia EM, Araujo JC, Aparicio A, Tu SM, Zurita AJ, Efstathiou E, Qiao W, Wen S, Gallick GE, Logothetis C. Modulation of soluble c-Met, bone turnover markers, angiogenic factors, and c-Met in men with mCRPC treated with cabozantinib. J Clin Oncol 31, 2013. PMID: None.
19. Quinn DI, Hamid O, Tsao-Wei D, Hu J, Pinski J, Schuckerman A, Daneshmand S, Groshen S, Raghaven D, Korn C, Massopust K, Ketchens C, Aparicio AM, Dorff TB. Gemcitabine, oxaliplatin, and paclitaxel (GOT) on a 2-weekly schedule in patients (PTS) with refractory germ cell carcinoma: A phase II study conducted at the University of Southern California. Ann Oncol 23(9):ix258-ix293, 2012. PMID: None.
20. Aparicio A, Sun, J, Ng Tang D, Arap W, Araujo J, Corn P, Tannir N, Wang X, Radtke A, Sharma P. A phase II study of ipilumimab plus androgen deprivation therapy in castration-sensitive prostate carcinoma. Cancer Research 72(6), 2012. PMID: None.
21. Aparicio A, Harzstark L, Lin E, Corn P, Araujo J, Tu S, Pagliaro L, Millikan R, Arap W, Kim J, Ryan C, Zurita A, Tannir N, Lin A, Small J, Mathew P, Jones D, Troncoso P, Thall P, Logothetis C. Characterization of the anaplastic prostate carcinomas: A prospective two-stage phase II trial of frontline carboplatin and docetaxel (CD) and salvage etoposide and cisplatin (EP). J Clin Oncol 29, 2011. PMID: None.
22. Tzeelpi V, Maity S, Zhang J, Liang S, Lu JF, Anh H, Kleb B, Efstathiou E, Navone N, Troncoso P, Logothetis C, Aparicio A. Molecular profiling of prostate cancer xenografts and human specimens reveals overexpression of UBE2C/UBCH10 and activation of aurora kinases in poorly differentiated neuroendocrine carcinoma of the prostate. Cancer Research 71(8):10.1158/1538-7445.AM2011-36, 2011. PMID: None.
23. Tzelepi V, Maity S, Zhang J, Karlou M, Liang S, Hoang A, Lu J, Kleb B, Efstathiou E, Navone N, Aparicio A, Troncoso P. Differential expression of UBE2C and ASCL1 in neuroendocrine carcinoma and adenocarcinoma of the prostate in xenograft models and human samples. USCAP Annual Meeting, San Antonio, TX, 2011. PMID: None.
24. Efstathiou E, Tu S, Aparicio A, Hoang A, Troncoso P, Smith L, Chieffo N, Molina A, Logothetis C. Use of "intracrine androgen signaling signature" to predict benefit from abiraterone acetate(AA) in patients with castrate-resistant prostate cancer (CRPC). J Clin Oncol 28(15s), 2010. PMID: None.
25. Jonasch E, Wood G, Matin S, Tamboli K, Do L, Pagliaro C, Aparicio AM, Araujo JC, Tannir NM. Presurgical bevacizumab in patients with metastatic clear cell renal cell carcinoma: A phase II study. J Clin Oncol 26(15S):275s, 2008. PMID: None.
26. Aparicio AM, Lin AM, Araujo JC, Logothetis CJ, Kim J, Pagliaro LC, Tu S, Guo C, Jones D, Thall P, Mathew P. Use of clinical features to select a chemotherapy-responsive variant of aggressive prostate cancer (PC). J Clin Oncol 26(15S):271s, 2008. PMID: None.
27. Aparicio A, North B, Yang J, Jelinek J, Guo C, Logothetis C, Navone N, Issa JP. DNA methylation profiles can discriminate prostate cancer phenotypes. Gordon Research Conference, Ventura, CA, 2008. PMID: None.
28. Cheung EM, Quinn DI, Tsao-Wei DD, Groshen SG, Aparicio AM, Twardowski P, Shatta GS, Lara Jr PN, Gandara DR. Phase II study of vorinostat (Suberoylanilide Hydroxamic Acid, SAHA) in patients with advanced transitional cell urothelial cancer (TCC) after platinum-based therapy--California Cancer Consortium/University of Pittsburgh NCI/CTEP-sponsored trial. J Clin Oncol 26(15S), 2008. PMID: None.
29. Tannir NM, Zurita AJ, Heymach JV, Tran HT, Pagliaro LC, Corn P, Aparicio AM, Ashe R, Wright JJ, Jonasch E. A randomized phase II trial of sorafenib versus sorafenib plus low-dose interferon-alfa: Clinical results and biomarker analysis. J Clin Oncol 26(15S), 2008. PMID: None.
30. Sonpavde G, Aparicio AM, Delaune R, Garbo LE, Rousey SR, Weinstein RE, Williams A, Zhan F, Boehm KA, Asmar L, Von Hoff DD. Azacitidine for castration-resistant prostate cancer progressing on combined androgen blockade. J Clin Oncol 26, 2008. PMID: None.
31. Luu TH, Leong L, Morgan R, McNamara M, Lim D, Portnow J, Frankel P, Aparicio A, Chew H, Gandara DR, Somlo G. Vorinostat (suberoylanilide hydroxamic acid) as salvage therapy in metastatic breast cancer (MBC): A California Cancer Consortium phase II study. J Clin Oncol 25(18S), 2007. PMID: None.
32. Dorff TB, Rupani R, Wei DT, Groshen S, Pinski J, Raghavan D, Quinn D, Aparicio A. POMB-ACE therapy for patients with international germ cell cancer collaborative group (IGCCCG) poor risk germ cell tumors (GCT): The USC experience. J Clin Oncol 24(18S), 2006. PMID: None.
33. Ramalingam S, Parise RA, Egorin MJ, Argiris A, Stoller R, l B, Aparicio A, Newman EM, Zwiebel J, Belani CP. Phase I study of vorinostat, a histone deacetylase (HDAC) inhibitor, in combination with carboplatin (Cb) and paclitaxel (P) for patients with advanced solid malignancies (NCI # 6922). J Clin Oncol 24(18S), 2006. PMID: None.
34. Barske L, Bollati V, Yang AS, Aparicio AM. A comparison of bisulfite-based DNA methylation assays for the measurement of DNA methylation changes induced by decitabine. AACR-NCI-EORTC International Conference Molecular Targets and Cancer Therapeutics:Discovery, Biology, and Clinical Applications, 2005. PMID: None.

Book Chapters

1. Tagawa ST, Aparicio A, Robinson B, Sing-Batra J, Golden E. Uncommon Cancers of the Prostate. In: Textbook of Uncommon Cancers. 5th. None, 2017.
2. Logothetis CJ, Kim J, Davis JW, Chapin BF, Kuban DA, Efstathiou E, Aparicio A. 98 Neoplasm of the Prostate. In: Holland-Frei Cancer Medicine. 9th. Wiley-Blackwell, 2017.
3. Logothetis CJ, Troncoso P, Kim J, Davis JW, Kuban DA, Mathew P, Aparicio A. Neoplasm of the Prostate. In: Cancer Medicine. 8th. People Medical Publishing House-USA, 1228-1254, 2010.
4. Aparicio A, Sharma P, Millikan RE. Experimental systemic therapy of metastatic urothelial cancer. In: UpToDate, Basow, DS(Ed), UpToDate, Waltham, MA. None. None, 2009.

Letters to the Editor

1. Aparicio A, Thall P, Logothetis C. Radiotherapy for metastatic prostate cancer. Lancet 394: 829-830, 2019.
2. Aparicio A, Logothetis CJ. Reply to J.B. Aragon-Ching and D. Dalela et al. J Clin Oncol 35: 917-918, 2017.